Jonathon DeBonis

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

This paper develops a mathematical framework to analyze molecular glues, showing that strong ternary complex binding affinity is key for performance, with degrader performance limited by catalytic efficiency and target half-life.

This study evaluates the pharmacokinetics of a human mAb in different mouse strains to identify suitable models for preclinical testing.

This paper develops a mathematical model to explain IL-12 pharmacokinetic desensitization, showing that reduced bioavailability, not increased clearance, best explains clinical data.

This paper develops a dynamic kinetic model of cell-free metabolism to optimize butanol production, identifying aldehyde/alcohol dehydrogenase as a key bottleneck.